Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Effects of E-Tonus in Moderate Parkinson's Disease (ETMOPARK)

8. november 2026 opdateret af: Brain and Mind

A Randomized, Double-blind, Sham-controlled, Crossover, Pilot Clinical Investigation, Evaluating the Short-term Effects of E-Tonus, a Wearable Electromagnetic Device, on Motor Symptoms in Adult Participants With Moderate Parkinson's Disease

The goal of this clinical trial is to evaluate the short-term effect of E-Tonus, a wrist-worn device that gives off a low-intensity pulsed electromagnetic field, on functional mobility in adults with moderate Parkinson's disease. It will also learn about the short-term safety profile of E-Tonus.

Studieoversigt

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

40

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

50 år til 75 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Adults aged 50-75 years;
  • Parkinson's disease (MDS diagnostic criteria)Hoehn & Yahr stage II to II.5 confirmed in the ON medication state;
  • At least one of the following MDS-UPDRS criteria must be met, reflecting the presence of clinically meaningful gait or balance impairment but still able to walk unaided:
  • MDS-UPDRS Gait (item 3.10) score = 2, OR
  • Freezing of gait (item 3.11) score ranging from 1 to 2, OR
  • Postural instability (item 3.12) score ranging from 1 to 2, OR
  • Walking & Balance (item 2.12) score = 2, OR
  • Freezing (item 2.13) score ranging from 1 to 2;
  • Stable dopaminergic therapy ≥4 weeks;
  • Predictable ON-state duration ≥2 consecutive hours.

Exclusion Criteria:

  • Severe axial motor impairment (pre-specified items rated 3 or 4) or investigator-judged fall/safety risk;
  • Pregnancy;
  • Electromagnetic hypersensitivity;
  • Postural hypotension, musculoskeletal, or vestibular disorders affecting balance;
  • Uncontrolled cardiac, pulmonary, major neurological, or metabolic disease;
  • Cognitive impairment (MoCA ≤22);
  • Implanted active medical device (e.g., DBS, pacemaker) or metal implant/tattoo at the wrist application site;
  • History of radial nerve injury on the device-bearing arm;
  • Legally protected vulnerable adults.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Støttende pleje
  • Tildeling: Randomiseret
  • Interventionel model: Crossover opgave
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Active E-Tonus

Participants wear E-Tonus on the wrist in the active condition, emitting low-frequency, low-intensity pulsed electromagnetic field stimulation, for approximately 30 minutes. In this crossover study, all participants receive both the active and sham conditions during a single study visit, in a randomized order, separated by a 30-minute washout period. Assessments are performed in the ON medication state.

Personal, portable, wrist-worn, non-invasive Class IIa electromagnetic stimulation device manufactured by A.F. Genese. It emits a low-frequency, low-intensity pulsed electromagnetic field with a controlled pulse width, delivering peripheral transcutaneous stimulation at the wrist. Used once, for approximately 30 minutes, during a single study visit, in addition to the participant's usual Parkinson's disease medication.

The same wrist-worn device in a sham configuration that emits no electromagnetic field. It is visually and physically indistinguishable from the active device, so that participants and investigators remain blinded. Used once, for approximately 30 minutes, during a single study visit.

Sham-komparator: Sham E-Tonus

Participants wear E-Tonus on the wrist in the sham condition, with no stimulation emitted, for approximately 30 minutes. The sham device is visually and physically indistinguishable from the active device. In this crossover study, all participants receive both the active and sham conditions during a single study visit, in a randomized order, separated by a 30-minute washout period. Assessments are performed in the ON medication state.

Personal, portable, wrist-worn, non-invasive Class IIa electromagnetic stimulation device manufactured by A.F. Genese. It emits a low-frequency, low-intensity pulsed electromagnetic field with a controlled pulse width, delivering peripheral transcutaneous stimulation at the wrist. Used once, for approximately 30 minutes, during a single study visit, in addition to the participant's usual Parkinson's disease medication.

The same wrist-worn device in a sham configuration that emits no electromagnetic field. It is visually and physically indistinguishable from the active device, so that participants and investigators remain blinded. Used once, for approximately 30 minutes, during a single study visit.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in instrumented Timed Up-and-Go (iTUG) 7-meter total task time: active vs. sham E-Tonus
Tidsramme: Baseline (before each device condition) and end-of-period (after approximately 30 minutes of device use), for each of the 2 device conditions within a single study visit (Day 1)

The iTUG test measures the time (in seconds) a participant needs to stand up from a chair, walk 7 meters, turn around, walk back and sit down again, from the start of the sit-to-stand transition to the end of the stand-to-sit transition. It is instrumented with an accelerometer. Two trials are performed at each time point and averaged. For each device condition (active and sham), the change from baseline to end-of-period is calculated. The outcome is the difference between active and sham conditions in this change. A greater reduction in time indicates better functional mobility.

Baseline (before each device condition) and end-of-period (after approximately 30 minutes of device use), for each of the 2 device conditions within a single study visit (Day 1)
Incidence, severity, seriousness and relatedness of adverse events (AEs) and adverse device effects (ADEs)
Tidsramme: From the start of the first device application (Day 1) through 48 hours after the last device application

Number of participants with adverse events and adverse device effects, described by severity (mild, moderate, severe), seriousness (serious or non-serious) and relationship to the device as assessed by the investigator, by device condition (active and sham).

From the start of the first device application (Day 1) through 48 hours after the last device application

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Ledende efterforsker: David DEVOS, Professor Neurologist, Service de Neurologie B : Neurologie vasculaire CHU de Lille - Hôpital Roger Salengro rue Emile Laine 59000 LILLE

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. december 2026

Primær færdiggørelse (Anslået)

1. april 2027

Studieafslutning (Anslået)

1. april 2027

Datoer for studieregistrering

Først indsendt

8. november 2026

Først indsendt, der opfyldte QC-kriterier

8. november 2026

Først opslået (Faktiske)

16. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

16. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

8. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • BM2601-AFGE01
  • IDRCB N° 2026-A01795-46 (Anden identifikator: ANSM (French National Agency for Medicines and Health Products Safety))

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

IPD-planbeskrivelse

There is no plan to share individual participant data. This is a small pilot investigation (40 participants), and the data are collected under French and European data protection regulations (GDPR), with participant consent limited to the purposes of this study. Aggregate results will be made available through scientific publication.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner